메뉴 건너뛰기




Volumn 36, Issue 3, 2005, Pages 250-261

Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: A technical review with interpretive guidelines

Author keywords

FISH; HER2; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

EID: 15544382365     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2004.11.010     Document Type: Article
Times cited : (156)

References (54)
  • 1
    • 0032843176 scopus 로고    scopus 로고
    • Adjuvant systemic therapy for primary breast cancer
    • F.J. Esteva, and G.N. Hortobagyi Adjuvant systemic therapy for primary breast cancer Surg. Clin. N. Am. 79 1999 1075 1090
    • (1999) Surg. Clin. N. Am. , vol.79 , pp. 1075-1090
    • Esteva, F.J.1    Hortobagyi, G.N.2
  • 2
    • 0036798273 scopus 로고    scopus 로고
    • Molecular prognostic factors for breast cancer metastasis and survival
    • F.J. Esteva, A.A. Sahin, and M. Cristofanilli Molecular prognostic factors for breast cancer metastasis and survival Semin. Radiat. Oncol. 12 2002 319 328
    • (2002) Semin. Radiat. Oncol. , vol.12 , pp. 319-328
    • Esteva, F.J.1    Sahin, A.A.2    Cristofanilli, M.3
  • 3
    • 0031732731 scopus 로고    scopus 로고
    • Integration of systemic chemotherapy in the management of primary breast cancer
    • F.J. Esteva, and G.N. Hortobagyi Integration of systemic chemotherapy in the management of primary breast cancer Oncologist 3 1998 1 14
    • (1998) Oncologist , vol.3 , pp. 1-14
    • Esteva, F.J.1    Hortobagyi, G.N.2
  • 4
    • 0032896905 scopus 로고    scopus 로고
    • Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for prediction response to adjuvant endocrine therapy in breast cancer
    • J.M. Harvey, G.M. Clark, and C.K. Osborne Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for prediction response to adjuvant endocrine therapy in breast cancer J. Clin. Oncol. 17 1999 1474 1481
    • (1999) J. Clin. Oncol. , vol.17 , pp. 1474-1481
    • Harvey, J.M.1    Clark, G.M.2    Osborne, C.K.3
  • 5
    • 0026650016 scopus 로고
    • Prognostic significance of HER-2 oncoprotein expression in breast cancer: A 30-year follow-up
    • S. Toikkanen, H. Helin, and J. Isola Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up J. Clin. Oncol. 10 1992 1044 1048
    • (1992) J. Clin. Oncol. , vol.10 , pp. 1044-1048
    • Toikkanen, S.1    Helin, H.2    Isola, J.3
  • 6
    • 0032850677 scopus 로고    scopus 로고
    • Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
    • M.A. Cobleigh, C.L. Vogel, and D. Tripathy Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J. Clin. Oncol. 17 1999 2639 2648
    • (1999) J. Clin. Oncol. , vol.17 , pp. 2639-2648
    • Cobleigh, M.A.1    Vogel, C.L.2    Tripathy, D.3
  • 7
    • 0024651788 scopus 로고
    • Localization of the human erbB-2 gene on normal and rearranged chromosome 17 to bands q12-21.32
    • N.C. Popescu, C.R. King, and M.H. Kraus Localization of the human erbB-2 gene on normal and rearranged chromosome 17 to bands q12-21.32 Genomics 4 1989 362 366
    • (1989) Genomics , vol.4 , pp. 362-366
    • Popescu, N.C.1    King, C.R.2    Kraus, M.H.3
  • 8
    • 0042208398 scopus 로고    scopus 로고
    • The HER-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy
    • J.S. Ross, J.A. Fletcher, and G.P. Linette The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy Oncologist 8 2003 307 325
    • (2003) Oncologist , vol.8 , pp. 307-325
    • Ross, J.S.1    Fletcher, J.A.2    Linette, G.P.3
  • 9
    • 37049183697 scopus 로고
    • Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene
    • D.J. Slamon, G.M. Clark, and S.C. Wong Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene Science 235 1987 177 182
    • (1987) Science , vol.235 , pp. 177-182
    • Slamon, D.J.1    Clark, G.M.2    Wong, S.C.3
  • 11
    • 0012890297 scopus 로고    scopus 로고
    • HER2 testing and correlation with efficacy of Trastuzumab therapy
    • M. Fornier, M. Risio, and C. Van Poznak HER2 testing and correlation with efficacy of Trastuzumab therapy Oncology 16 2002 1340 1352
    • (2002) Oncology , vol.16 , pp. 1340-1352
    • Fornier, M.1    Risio, M.2    Van Poznak, C.3
  • 12
    • 0035189256 scopus 로고    scopus 로고
    • Current status of HER2 testing: Caught between a rock and a hard place
    • S.J. Schnitt, and T.W. Jacobs Current status of HER2 testing: caught between a rock and a hard place Am. J. Clin. Pathol. 116 2001 806 810
    • (2001) Am. J. Clin. Pathol. , vol.116 , pp. 806-810
    • Schnitt, S.J.1    Jacobs, T.W.2
  • 13
    • 0035496541 scopus 로고    scopus 로고
    • The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis
    • S.A. Eccles The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis J. Mammary Gland Biol. Neoplasia 6 2001 393 406
    • (2001) J. Mammary Gland Biol. Neoplasia , vol.6 , pp. 393-406
    • Eccles, S.A.1
  • 14
    • 0034766736 scopus 로고    scopus 로고
    • Biology of HER2 and its importance in breast cancer
    • Y. Yarden Biology of HER2 and its importance in breast cancer Oncology 61 Suppl. 2 2001 1 13
    • (2001) Oncology , vol.61 , Issue.SUPPL. 2 , pp. 1-13
    • Yarden, Y.1
  • 16
    • 0035873962 scopus 로고    scopus 로고
    • Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message
    • R.R. Tubbs, J.D. Pettay, and P.C. Roche Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message J. Clin. Oncol. 19 2001 2714 2721
    • (2001) J. Clin. Oncol. , vol.19 , pp. 2714-2721
    • Tubbs, R.R.1    Pettay, J.D.2    Roche, P.C.3
  • 17
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med. 344 2001 783 792
    • (2001) N. Engl. J. Med. , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3
  • 18
    • 1842614241 scopus 로고    scopus 로고
    • Docetaxel combined with Trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: A multi-institutional phase II trial
    • K.L. Tedesco, A.D. Thor, and D.H. Johnson Docetaxel combined with Trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial J. Clin. Oncol. 22 2004 1071 1077
    • (2004) J. Clin. Oncol. , vol.22 , pp. 1071-1077
    • Tedesco, K.L.1    Thor, A.D.2    Johnson, D.H.3
  • 19
    • 0036467826 scopus 로고    scopus 로고
    • Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
    • C.L. Vogel, M.A. Cobleigh, and D. Tripathy Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J. Clin. Oncol. 20 2002 719 726
    • (2002) J. Clin. Oncol. , vol.20 , pp. 719-726
    • Vogel, C.L.1    Cobleigh, M.A.2    Tripathy, D.3
  • 20
    • 0035868668 scopus 로고    scopus 로고
    • 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology
    • R.C. Bast, J.P. Ravdin, and D.F. Hayes 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology J. Clin. Oncol. 19 2001 1865 1878
    • (2001) J. Clin. Oncol. , vol.19 , pp. 1865-1878
    • Bast, R.C.1    Ravdin, J.P.2    Hayes, D.F.3
  • 21
    • 0344453811 scopus 로고    scopus 로고
    • The clinical evaluation of HER2 status: Which test to use?
    • J. Bartlett, E. Mallon, and T. Cooke The clinical evaluation of HER2 status: which test to use? J. Pathol. 199 2003 411 417
    • (2003) J. Pathol. , vol.199 , pp. 411-417
    • Bartlett, J.1    Mallon, E.2    Cooke, T.3
  • 22
    • 0024337144 scopus 로고
    • Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    • D.J. Slamon, W. Godolphin, and L. Jones Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712
    • (1989) Science , vol.244 , pp. 707-712
    • Slamon, D.J.1    Godolphin, W.2    Jones, L.3
  • 23
    • 0037384049 scopus 로고    scopus 로고
    • Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres
    • M. Dowsett, J. Bartlett, and J.O. Ellis Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres J. Pathol. 199 2003 418 423
    • (2003) J. Pathol. , vol.199 , pp. 418-423
    • Dowsett, M.1    Bartlett, J.2    Ellis, J.O.3
  • 24
    • 0037099732 scopus 로고    scopus 로고
    • Evaluation of HER2 gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens
    • M.F. Press, D.J. Slamon, and K.J. Flom Evaluation of HER2 gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens J. Clin. Oncol. 20 2002 3095 3105
    • (2002) J. Clin. Oncol. , vol.20 , pp. 3095-3105
    • Press, M.F.1    Slamon, D.J.2    Flom, K.J.3
  • 25
    • 0037325177 scopus 로고    scopus 로고
    • Current perspectives on HER2 testing: A review of national testing guidelines
    • M. Bilous, M. Dowsett, and W. Hanna Current perspectives on HER2 testing: a review of national testing guidelines Mod. Pathol. 16 2003 173 182
    • (2003) Mod. Pathol. , vol.16 , pp. 173-182
    • Bilous, M.1    Dowsett, M.2    Hanna, W.3
  • 26
    • 0033871534 scopus 로고    scopus 로고
    • HER-2/neu testing in breast carcinoma: A combined immunohistochemical and fluorescence in situ hybridization approach
    • R.L. Ridolfi, M.R. Jamehdor, and J.M. Arber HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach Mod. Pathol. 13 2000 866 873
    • (2000) Mod. Pathol. , vol.13 , pp. 866-873
    • Ridolfi, R.L.1    Jamehdor, M.R.2    Arber, J.M.3
  • 27
    • 2142758687 scopus 로고    scopus 로고
    • HER-2 testing in breast cancer using parallel tissue-based methods
    • H. Yaziji, L.C. Goldstein, and T.S. Barry HER-2 testing in breast cancer using parallel tissue-based methods JAMA 291 2004 1972 1977
    • (2004) JAMA , vol.291 , pp. 1972-1977
    • Yaziji, H.1    Goldstein, L.C.2    Barry, T.S.3
  • 28
    • 0037024478 scopus 로고    scopus 로고
    • Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831
    • P.C. Roche, V.J. Suman, and R.B. Jenkins Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831 J. Natl. Cancer Inst. 94 2002 855 857
    • (2002) J. Natl. Cancer Inst. , vol.94 , pp. 855-857
    • Roche, P.C.1    Suman, V.J.2    Jenkins, R.B.3
  • 29
    • 0037023986 scopus 로고    scopus 로고
    • Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience
    • S. Paik, J. Bryant, E. Tan-Chiu, and E. Romond Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience J. Natl. Cancer Inst. 94 2002 852 854
    • (2002) J. Natl. Cancer Inst. , vol.94 , pp. 852-854
    • Paik, S.1    Bryant, J.2    Tan-Chiu, E.3    Romond, E.4
  • 30
    • 0028221475 scopus 로고
    • Optimization of immunohistochemical detection of ERBB2 in human breast cancer: Impact of fixation
    • F. Penault-Llorca, J. Adelaide, and G. Houvenaeghel Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation J. Pathol. 173 1994 65 75
    • (1994) J. Pathol. , vol.173 , pp. 65-75
    • Penault-Llorca, F.1    Adelaide, J.2    Houvenaeghel, G.3
  • 31
    • 0028641571 scopus 로고
    • C-erB-2 immunostaining: Problems with interpretation
    • E.W. Kay, C.J. Walsh, and M. Cassidy C-erB-2 immunostaining: problems with interpretation J. Clin. Pathol. 47 1994 816 822
    • (1994) J. Clin. Pathol. , vol.47 , pp. 816-822
    • Kay, E.W.1    Walsh, C.J.2    Cassidy, M.3
  • 32
    • 0038078174 scopus 로고    scopus 로고
    • Conference summary, strategic science symposium: HER-2/neu testing of breast cancer patients in clinical practice
    • R.J. Zarbo, and E.H. Hammond Conference summary, strategic science symposium: HER-2/neu testing of breast cancer patients in clinical practice Arch. Pathol. Lab. Med. 127 2003 549 553
    • (2003) Arch. Pathol. Lab. Med. , vol.127 , pp. 549-553
    • Zarbo, R.J.1    Hammond, E.H.2
  • 33
    • 0036314362 scopus 로고    scopus 로고
    • Clinical laboratory assays for HER-2/neu amplification and overexpression: Quality assurance, standardization, and proficiency testing
    • Cell Markers and Cytogenetics Committees College of American Pathologists Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing Arch. Pathol. Lab. Med. 126 2002 803 808
    • (2002) Arch. Pathol. Lab. Med. , vol.126 , pp. 803-808
  • 34
    • 0034327895 scopus 로고    scopus 로고
    • Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
    • G. Pauletti, S. Dandekar, and H. Rong Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry J. Clin. Oncol. 18 2000 3651 3664
    • (2000) J. Clin. Oncol. , vol.18 , pp. 3651-3664
    • Pauletti, G.1    Dandekar, S.2    Rong, H.3
  • 35
    • 0036161321 scopus 로고    scopus 로고
    • HER2 testing in patients with breast cancer: Poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization
    • E.A. Perez, P.C. Roche, and R.B. Jenkins HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization Mayo Clin. Proc. 77 2002 148 154
    • (2002) Mayo Clin. Proc. , vol.77 , pp. 148-154
    • Perez, E.A.1    Roche, P.C.2    Jenkins, R.B.3
  • 36
    • 0002860255 scopus 로고    scopus 로고
    • Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH)
    • R.D. Mass, M. Press, and S. Anderson Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH) [abstract 85] Proc. Am. Soc. Clin. Oncol. 20 2001 22a
    • (2001) Proc. Am. Soc. Clin. Oncol. , vol.20
    • Mass, R.D.1    Press, M.2    Anderson, S.3
  • 37
    • 2342545547 scopus 로고    scopus 로고
    • Fluorescence in situ hybridization
    • J.M.S. Bartlett Fluorescence in situ hybridization Methods Mol. Med. 97 2004 77 87
    • (2004) Methods Mol. Med. , vol.97 , pp. 77-87
    • Bartlett, J.M.S.1
  • 38
    • 0034018946 scopus 로고    scopus 로고
    • Laboratory assessment of the status of HER-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridization assays
    • S. Wang, M.H. Saboorian, and E.P. Frenkel Laboratory assessment of the status of HER-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridization assays J. Clin. Pathol. 53 2000 374 381
    • (2000) J. Clin. Pathol. , vol.53 , pp. 374-381
    • Wang, S.1    Saboorian, M.H.2    Frenkel, E.P.3
  • 39
    • 2042467574 scopus 로고    scopus 로고
    • HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: A single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring
    • P. Lal, P.A. Salazar, and C.A. Hudis HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring Am. J. Clin. Pathol. 121 2004 631 636
    • (2004) Am. J. Clin. Pathol. , vol.121 , pp. 631-636
    • Lal, P.1    Salazar, P.A.2    Hudis, C.A.3
  • 40
    • 4844228676 scopus 로고    scopus 로고
    • Comparative assays for the HER-2/neu oncogene status in breast cancer
    • J.M. Vera-Roman, and L.A. Rubio-Martinez Comparative assays for the HER-2/neu oncogene status in breast cancer Arch. Pathol. Lab. Med. 128 2004 627 633
    • (2004) Arch. Pathol. Lab. Med. , vol.128 , pp. 627-633
    • Vera-Roman, J.M.1    Rubio-Martinez, L.A.2
  • 41
    • 85059046809 scopus 로고    scopus 로고
    • The influence of polysomy 17 (CEP17+) on HER2 protein expression in carcinoma of the breast
    • E. Downs-Kelly, M. Stoler, and R. Tubbs The influence of polysomy 17 (CEP17+) on HER2 protein expression in carcinoma of the breast Mod. Pathol. 17 2004 29A
    • (2004) Mod. Pathol. , vol.17
    • Downs-Kelly, E.1    Stoler, M.2    Tubbs, R.3
  • 42
    • 0036183416 scopus 로고    scopus 로고
    • Aneusomy 17 in breast cancer: Its role in HER-2/neu protein expression and implications for clinical assessment of HER-2/neu status
    • S. Wang, H. Saboorian, and E.P. Frenkel Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implications for clinical assessment of HER-2/neu status Mod. Pathol. 15 2002 137 145
    • (2002) Mod. Pathol. , vol.15 , pp. 137-145
    • Wang, S.1    Saboorian, H.2    Frenkel, E.P.3
  • 44
    • 0033932514 scopus 로고    scopus 로고
    • Effects of formalin tissue fixation and processing on immunohistochemistry
    • M. Werner, A. Chott, and A. Fabiano Effects of formalin tissue fixation and processing on immunohistochemistry Am. J. Surg. Pathol. 24 2000 1016 1019
    • (2000) Am. J. Surg. Pathol. , vol.24 , pp. 1016-1019
    • Werner, M.1    Chott, A.2    Fabiano, A.3
  • 45
    • 0346125406 scopus 로고    scopus 로고
    • TOP2A and HER-2 amplification in fine needle aspirates from breast cancer
    • A.M. Bofin, B. Ytterhus, and B.M. Hagmar TOP2A and HER-2 amplification in fine needle aspirates from breast cancer Cytopathology 14 2003 314 319
    • (2003) Cytopathology , vol.14 , pp. 314-319
    • Bofin, A.M.1    Ytterhus, B.2    Hagmar, B.M.3
  • 46
    • 0031777591 scopus 로고    scopus 로고
    • Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder?
    • J.M. Bartlett, A.D. Watters, and S.A. Ballantyne Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder? Br. J. Cancer 77 1998 2193 2198
    • (1998) Br. J. Cancer , vol.77 , pp. 2193-2198
    • Bartlett, J.M.1    Watters, A.D.2    Ballantyne, S.A.3
  • 47
    • 0032729607 scopus 로고    scopus 로고
    • Chromosomal aberrations in transitional cell carcinoma that are predictive of disease outcome are independent of polyploidy
    • J.M.S. Bartlett, L. Adie, and A.D. Watters Chromosomal aberrations in transitional cell carcinoma that are predictive of disease outcome are independent of polyploidy BJU Int. 84 1999 775 779
    • (1999) BJU Int. , vol.84 , pp. 775-779
    • Bartlett, J.M.S.1    Adie, L.2    Watters, A.D.3
  • 48
    • 0033984977 scopus 로고    scopus 로고
    • Aneusomy of chromosomes 7 and 17 predicts the recurrence of transitional cell carcinoma of the urinary bladder
    • A.D. Watters, S.A. Ballantyne, and J.J. Going Aneusomy of chromosomes 7 and 17 predicts the recurrence of transitional cell carcinoma of the urinary bladder BJU Int. 85 2000 42 47
    • (2000) BJU Int. , vol.85 , pp. 42-47
    • Watters, A.D.1    Ballantyne, S.A.2    Going, J.J.3
  • 49
    • 0035162262 scopus 로고    scopus 로고
    • Evaluating HER2 amplification and overexpression in breast cancer
    • J.M.S. Bartlett, J. Reeves, and P. Stanton Evaluating HER2 amplification and overexpression in breast cancer J. Pathol. 195 2001 422 428
    • (2001) J. Pathol. , vol.195 , pp. 422-428
    • Bartlett, J.M.S.1    Reeves, J.2    Stanton, P.3
  • 50
    • 4043100559 scopus 로고    scopus 로고
    • DNA ploidy and cell cycle analysis in breast cancer
    • J.S. Ross, G.P. Linette, and J. Stec DNA ploidy and cell cycle analysis in breast cancer Am. J. Clin. Pathol. 120 2003 S72 S84
    • (2003) Am. J. Clin. Pathol. , vol.120
    • Ross, J.S.1    Linette, G.P.2    Stec, J.3
  • 51
    • 2142660746 scopus 로고    scopus 로고
    • High-quality HER2 testing: Setting a standard for oncologic biomarker assessment
    • E.L. Wiley, and L.K. Diaz High-quality HER2 testing: setting a standard for oncologic biomarker assessment JAMA 291 2004 1972 1973
    • (2004) JAMA , vol.291 , pp. 1972-1973
    • Wiley, E.L.1    Diaz, L.K.2
  • 52
    • 0036314362 scopus 로고    scopus 로고
    • Clinical laboratory assays for Her2/neu amplification and overexpression; Quality assurance, standardization, and proficiency testing
    • R. Nagle, R. Tubbs, and P. Roche Clinical laboratory assays for Her2/neu amplification and overexpression; quality assurance, standardization, and proficiency testing Arch. Pathol. Lab. Med. 126 2002 803 808
    • (2002) Arch. Pathol. Lab. Med. , vol.126 , pp. 803-808
    • Nagle, R.1    Tubbs, R.2    Roche, P.3
  • 53
    • 0036094229 scopus 로고    scopus 로고
    • Gold-facilitated in situ hybridization: A bright field autometallographic alternative to fluorescence in situ hybridization for detection of HER-2/neu gene amplification
    • R. Tubbs, J. Pettay, and M. Skacel Gold-facilitated in situ hybridization: a bright field autometallographic alternative to fluorescence in situ hybridization for detection of HER-2/neu gene amplification Am. J. Pathol. 160 2002 1589 1595
    • (2002) Am. J. Pathol. , vol.160 , pp. 1589-1595
    • Tubbs, R.1    Pettay, J.2    Skacel, M.3
  • 54
    • 0033694650 scopus 로고    scopus 로고
    • Chromogenic in situ hybridization: A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples
    • M. Tanner, D. Gancberg, and A. Di Leo Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples Am. J. Pathol. 157 2000 1467 1472
    • (2000) Am. J. Pathol. , vol.157 , pp. 1467-1472
    • Tanner, M.1    Gancberg, D.2    Di Leo, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.